Science news

<<  return



European Society of Cardiology 2014 Congress: Treatment with alirocumab (Sanofi/Regeneron Pharmaceuticals), an investigational proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in significant reductions in LDL cholesterol in various groups of patients who received the drug, including individuals at high risk for cardiovascular events currently taking a maximally tolerated statin dose. After 65 weeks of treatment, the results suggested alirocumab significantly reduced the risk of major events compared with those who received placebo and a maximally tolerated statin.